<DOC>
	<DOCNO>NCT02129816</DOCNO>
	<brief_summary>Overactive bladder ( OAB ) enigmatic condition treat symptomatically anticholinergic drug ( gold standard 2013 ) . In clinical pilot study find trend high reduction micturition frequency Bryophyllum pinnatum group - treat chew tablet contain 50 % dry BP leaf press juice - placebo group ( n=20 , p=0.064 ) Hypothesis : To test superior effectivity Bryophyllum versus Placebo treatment OAB need number ( Purpose 1 ) ass experimental arm side effect BP comparison standard drug ( Vesicare ) clincial trial ( Purpose 2 ) .</brief_summary>
	<brief_title>Bryophyllum Pinnatum Versus Solifenacin Versus Placebo Overactive Bladder</brief_title>
	<detailed_description>- In US nation-wide survey , low urinary tract symptom one strong predictor patient seek complementary alternative medicine ( CAM ) care . In comparison general gynecological patient , urogynecological patient particularly prone seek help CAM . Moreover different CAM option , herbal medication one preferred treatment . However , effectiveness CAM regard OAB yet adequately objectively evaluate . Therefore , timely essential elucidate mode action well prove efficacy herbal treatment translational approach include comprehensive vitro experimentation randomize controlled clinical trial . Bryophyllum pinnatum specially flavonoid component show muscle relax effect porcine bladder strip . - Study Design : Multicenter , prospective , double-blind randomize , placebo-controlled cross-over study , phase III test superiority Bryophyllum pinnatum ( BP ) placebo treatment overactive bladder . - In cross-over trial total 30 patient need proof superiority BP placebo ( 5 randomization bloc , 6 patient ) . Each patient get three study drug ( BP , Solifenacin , Placebo ) double-blind randomization . The number patient calculate post-hoc analysis base primary endpoint previous study ( reduction micturition rates/24hours ; 9.5 ( SD2.2 ) 7.8 ( SD1.2 ) Bryophyllum versus 9.3 ( SD1.8 ) 9.1 ( SD1.6 ) placebo ) , assumption normal data distribution power 80 % patient number 2x20 . Plus 10 % non-parametric test case non-normal distribution ( Wilcoxon ) add , generate number 2x22 patient . - In order facilitate equality randomization , investigator choose cross-over design . Due length study time , drop-out rate rise 10 20 % yield assumption equal block randomization number 30 patient . Additionally , explorative arm contain standard medication Vesicare insert , great clinical interest . For explorative comparative arm exist data would allow power calculation . - This follow-up study give compel answer efficacy non-efficacy BP well safety BP respect placebo possible answer position regard standard medication Vesicare .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>OAB ( &gt; 8 micturitions/24 hour , associate urge symptom ) postmenopausal woman cystoscopy exclude bladder carcinoma carcinoma situ write oral informed consent urinary tract infection intermittent catheter asservated sample ( &gt; 1000 bacterias/ml ) intake bladder affect drug like anticholinergic , diuretic , muscle relax medication phytotherapeutics last three month neurological condition stroke , multiple sclerosis , spinal cord injury Parkinsons 's disease postvoid residual volume â‰¥100 ml lactose intolerance contraindication Solifenacin</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Female</keyword>
	<keyword>Postmenopause</keyword>
</DOC>